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Abstract: Human cytomegalovirus (HCMV) establishes either a latent (non-productive) or lytic
(productive) infection depending upon cell type, cytokine milieu and the differentiation status of
the infected cell. Undifferentiated cells, such as precursor cells of the myeloid lineage, support a
latent infection whereas terminally differentiated cells, such as monocytes or dendritic cells are an
environment conducive to reactivation and support a lytic infection. The mechanisms which regulate
HCMV in either a latent or lytic infection have been the focus of intense investigation with a view to
developing novel treatments for HCMV-associated disease which can have a heavy clinical burden
after reactivation or primary infection in, especially, the immune compromised. To this end, a number
of studies have been carried out in an unbiased manner to address global changes occurring within
the latently infected cell to address the molecular changes associated with HCMV latency. In this
review, we will concentrate on the proteomic analyses which have been carried out in undifferentiated
myeloid cells which either stably express specific viral latency associated genes in isolation or on cells
which have been latently infected with virus.
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1. Introduction
Human cytomegalovirus (HCMV) is a species-specific pathogen which is carried by approximately
60–80% of the population, depending on demographics [1]. Front-line anti-virals for HCMV are limited
due to poor bioavailability and drug resistance. Additionally, currently available drugs target the
lytic phase of infection rather than the latent phase (the phases of the lifecycle are described in detail
below) [2,3]. Therefore, the need to target latently infected cells could be crucial, particularly in settings
such as solid organ or stem cell transplantation where latent virus in the graft itself can be transferred to
an immune-suppressed donor or a seropositive graft recipient’s own virus can reactivate. In this review,
we will discuss how understanding the cellular changes which occur during latency, by studying the
latency-induced proteome, may not only lead to an enhanced understanding of the mechanisms of viral
latency and reactivation but also aid the development of novel therapeutics to target the latent virus
reservoir. For instance, latently infected cells can be killed by targeting latency-associated changes in
cellular proteins (such as virally induced changes in expression of the cellular MRP-1 protein, detailed
below) or killed by targeting the viral protein expressed during latency directly (as detailed for US28,
below). Other identified changes have also highlighted mechanisms used during latency to optimize
conditions for the virus, such as regulation of cellular genes S100A8/A9 and HCLS1.
2. HCMV Lytic and Latent Lifecycle
HCMV is a large double-stranded DNA virus with a protracted lytic lifecycle; up to 72 h in
some cell types. This commences with immediate early (IE) gene expression, then early (E) gene
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expression and finally, late gene expression (L) [4]. The lytic lifecycle can take place in a wide range of
terminally differentiated cell types, including fibroblasts, macrophages’ endothelial cells, resulting in
full productive virus replication. The ability of the virus to establish a lifelong infection in the host is,
at least in part, due to the ability of the virus to also be able to establish a latent infection during which
time viral genome is carried in cells but IE gene expression is suppressed and infectious virions are not
produced [5]. One established site of HCMV latency is in the cells of the myeloid lineage [5] where,
in vivo, virus is carried in myeloid progenitors such as CD34+ progenitor cells and their derivative
CD14+ monocytes. Then, as the cells differentiate along the myeloid lineage to terminally differentiated
cell types such as macrophages or dendritic cells, the virus reactivates leading to the initiation of IE
gene expression, the full temporal lytic gene cascade and ultimately, progeny virions [5].
2.1. Viral Gene Expression during HCMV Latency
Whilst latent infection in myeloid progenitor cells is marked by general suppression of IE gene
expression and a lack of infectious virion production, the exact latency-associated viral transcription
programme is far from clear. A number of studies have attempted to define the viral genes which are
expressed during latency. These analyses used targeted primers for known viral genes suspected to
be expressed during latency to detect viral transcripts in latently infected cells. Such studies have
led to the identification of viral genes such as UL138, US28, UL144, UL81-82ast (LUNA) and UL111A
(viral IL10) [6–11]. More recently, unbiased screening has identified different subsets of viral genes in
both experimentally and naturally latent myeloid cells [12–16]. HCMV also encodes a number of viral
miRNAs [17] which have been shown not only to be expressed during lytic infection but also during
latency [18–20]. Therefore, whilst the exact viral gene expression profile during latent infection has not
been categorically defined, it is now clear that, far from the genome being carried silently in latently
infected cells, latent infection is accompanied by the expression of a number of viral genes which are
likely to affect cellular gene expression to optimise latent carriage of the virus.
2.2. Cellular Transcriptome Analysis of HCMV Latency
Changes in the cellular RNAs resulting from latent infection of myeloid progenitors have
included analyses of changes in the cellular miRNAome [19,21,22] as well as changes in cellular
mRNAs based on either bulk or single cell RNA analyses [23–28]. These studies have led to the
identification of a number of ways in which the virus manipulates host cell RNA expression during
latency. For example, the downregulation of cellular hsa-miR-92a leads to a manipulation of the
chemokine CCL8 [29], a chemokine previously identified to be upregulated during latency in the
latency associated secretome [30]. It also appears that the viral genes expressed during latency regulate
cellular genes involved in immune suppression and can drive latently infected myeloid cells into
an anergic state [25,28]. Additionally, virus binding to monocytes has been shown to alter their
transcriptome, changing the phenotype of the cells by, for example, regulating PI3 kinase and Erk/
MAP kinase signaling [24]. Indeed, it has been suggested that the binding of HCMV to the cell
membrane causes reprogramming of monocyte survival and differentiation [31]. Some transcriptome
analyses during HCMV latency have identified changes of genes involved in cell survival and immune
regulation such as PEA-15 [23], which has since been validated and a mechanism defined [32,33].
Changes in MHC class II [23] during latency have also been identified and at least one mechanism
for this change has been defined [34,35]. These studies have been informative but one way to obtain
a more comprehensive understanding of changes in protein expression during latency is to analyse
virally induced changes in the total proteome in an unbiased manner.
3. Studying the Proteome
During lytic infection, temporal changes in the viral proteome [4] as well as changes in the cell
proteome mediated by lytic infection have been extensively analysed [4,36]. Such studies have been
expanded upon, using for instance shRNA or CRISP-R libraries, to identify mechanisms by which
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viral-viral or viral-cellular protein–protein interactions regulate both cellular and viral gene expression
during lytic infection [4,37]. Such high-throughput approaches to understanding HCMV lytic infection
have been recently reviewed [37–39]. In this review, we discuss total proteomic analyses that have
been carried out to interrogate cellular changes during HCMV latency.
3.1. Total Proteomic Changes during HCMV Latency
One difficulty when analysing total proteomic changes during latency is that the levels of infection
are often low and it can be difficult to identify the latently infected cell in a mixed population. One
way to address this is to generate a virus which expresses a fluorescent tag during a latent infection
to allow the latently infected cells to be separated by FACS from the total cell population. Routinely,
GFP expression under control of the SV40 promoter has been employed by a number of groups to
identify latently infected cells. However, GFP expression can tend to wane over time and so alternative
fluorescent tags to mark latently infected cells have also been derived such as SV40-mCherry or
GATA2-mCherry in which mCherry is under the control of the GATA2 transcription factor, which
is known to activate a number of viral latency-associated genes in undifferentiated myeloid cells.
Proteomic studies on such cells have led to the identification of a number of cellular processes which
are affected by HCMV latent infection of myeloid cells [35,40,41].
3.2. HCLS1
One cellular protein which is substantially upregulated during HCMV latent infection of CD14+
monocytes is Haematopoietic lineage cell-specific protein 1 (HCLS1). HCLS1 is expressed in cells
of the haematopoietic lineage, such as CD34+ and CD14+ monocytes [42], and is known to be a
cortactin homologue that is involved in the stabilisation of actin filaments thereby aiding myeloid cell
motility and adhesion to the endothelial cell layer [43]. HCLS1 has also been reported to enhance
transendothelial cell migration of NK cells [44]. All of these properties could potentially aid virus
latent carriage and dissemination and it was found that latently infected cells are, indeed, more motile
than uninfected monocytes and are more able to adhere to, and transit, the endothelial cell layer [40].
3.3. S100A8/A9
In addition to the identification of upregulated cellular proteins, proteomic analysis of latently
infected monocytes has also identified a number of downregulated cellular proteins. Two of these,
which were equally downregulated, were S100A8 and S100A9 which often function together as a dimer.
One known property of S100A8/A9 is the ability to chemoattract cells, such as neutrophils [45]. Studies
on latently infected cells showed that neutrophils are capable of killing latently infected cells at very
high E:T (effector to target cell) ratios. At physiological E:T ratios, however, neutrophils do not kill
latently infected cells which appears to be, at least in part, due to the downregulation of S100A8/A9 [41].
4. Proteome Changes Induced by Expression of Latency-Associated Proteins in Isolation
Though unbiased proteomic screens are a powerful way to interrogate latency-associated changes
in cellular proteins, some targets could possibly be missed, especially because viral latency-associated
gene expression is known to be very low in the latently infected cells. One way to address this is
to overexpress putative latency associated genes in isolation. Another advantage of this targeted
approach is that a screen which identifies changes in total cellular proteins induced by latency will
not, inherently, identify which viral gene product has caused these changes. Therefore, a number
of studies have analysed changes in myeloid cells which over-express specific latency-associated
proteins. To date, this has been carried out for two viral genes known to be expressed during latency
by overexpressing them in THP1 myelomonocytic cells, a cell type known to support HCMV latency
and reactivation [7,46,47].
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4.1. US28
US28 is a viral latency-associated transcript which, like all known viral latency associated genes,
is also expressed during lytic infection. US28 mRNA has been detected during both experimental and
natural latency [7–9,48] and encodes a membrane associated G-protein coupled receptor (GPCR) with
seven transmembrane helices which is involved in a number of signalling pathways. During latency,
US28 is expressed at the protein level as evidenced by the observations that latently infected cells can
be killed by a drug which targets the US28 protein [49] as well as the observation that US28 protein
plays a role in myeloid differentiation during HCMV latency in humanised mice [50].
In all but one study [7,8,25,35,41,48,50,51], US28 has been shown to be essential for the establishment
and maintenance of latency in the myeloid lineage. One reported mechanism by which US28 regulates
latency involves activation of STAT3 in the iNOS and NO pathway [25]. US28 is also known to be able
to initiate different signalling pathways in a cell-type-specific manner. For instance, expression of US28
in undifferentiated myelomonocytic THP1 cells results in changes in the cellular phosphotome which
are quite different to those induced by US28 in PMA-differentiated THP1 cells. For example, ERK,
CREB and MSK signalling is downregulated by US28 in undifferentiated THP1 cells but, in terminally
differentiated cells, these pathways are stimulated by US28 and such changes have been shown to
differentially regulate expression from the MIEP [48,52].
Changes in the total cell proteome resulting from US28 expression in undifferentiated THP1 cells
have also been analysed [35]. Of particular interest was the downregulation of a number of PYHIN
family proteins by US28 which included MNDA (myeloid cell nuclear differentiation antigen) and
IFI16 (Interferon-Inducible Protein 16). PYHIN proteins are so-called because of their common HIN200
domains and many members of this family of proteins have been shown to play a role in innate immune
evasion. For example, IFI16 has been shown to be important for dsDNA virus sensing in certain cell
types [53–55], can modulate viral gene expression during lytic HCMV infection [56,57] and is known
to affect infection of other herpesviruses such as HSV-1 [58]. Additionally, IFI16 has been shown to
activate NFkB signalling [59–61] and, during HCMV latent infection, downregulation of IFI16 by US28
appears to suppress NFkB-mediated activation of the MIEP, thereby helping to maintain latency [35].
4.2. UL138
UL138 is a latency-associated transcript which is known to be expressed during both experimental
and natural latency [6,14,16,62] as well as lytic infection. The presence of UL138 is required for the
establishment of latency in a number of in vitro systems [63] and the regulation and functions of
UL138 during latency has been the subject of much research [64–68]. To help address the role of UL138
during latency, the changes in the cell plasma membrane resulting from its overexpression has been
analysed [69]. Major changes in the plasma membrane profile were identified as a result of expression
of UL138 and one protein which was identified as being massively down-regulated by UL138 was
the Multi-Drug Resistance Protein-1 (MRP-1). MRP-1 acts as a drug transporter protein and pumps
vinca alkaloids and other toxins out of the cell. It is unclear at present how this benefits the virus
during latency although the regions for UL138-mediated MRP-1 degradation have been identified [68].
A direct effect of such downregulation of MRP-1 is that latently infected cells are less able to transport,
e.g., vincristine out of the cell. Consistent with this, studies showed that latently infected cells were
more sensitive to vincristine, and vincristine targeted and killed latently infected CD34+ cells [69]. The
possible therapeutic potential of this is a topic of ongoing research.
5. Concluding Remarks
A comprehensive account of all changes in the cell resulting from HCMV latency is still some way
off. However, such analyses have begun to give us some insight as to how the virus manipulates the
cell during latency to optimise latent carriage. In this review, we have concentrated on changes to the
cellular proteome. Many of these changes (summarised in Figure 1) have identified mechanisms by
Pathogens 2020, 9, 590 5 of 9
which latent infection modifies, transendothelial migration and avoidance of neutrophil killing. More
targeted approaches have also identified changes in the cell brought about by expression of specific
latency-associated viral genes in isolation and have shown how this results in changes in the cell that
help evade host innate immune responses but other changes also render cells more sensitive to, e.g.,
potentially therapeutic toxins. Taken together, such analyses help us to understand the biological
mechanism of latent virus carriage but also identify changes in the phenotype of latently infected cells
that could become potential “Achilles heels” for them to be targeted therapeutically.
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MRP-1 is downregulated during latency by latency associated protein UL138 which renders cells 
sensitive to drug-mediated killing. 
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Figure 1. Cellular protein changes identified from unbiased proteomic screens in Human
cytomegalovirus (HCMV) latency. (1) HCLS1 is upregul t which regulat s actin stabilisation
and, therefore, cell motility leading to enhanced endothelial cell attachment and transit. (2) S100A8/A9
are downregulated preventing the chemoattraction of neutrophils which could otherwise target and
kill latently infected cells. (3) IFI16 is downregulated by latency-associated protein US28 and prevents
NFkB activation of the MIEP and therefore helps aid the maintenance of latency. (4) Drug transporter
MRP-1 is downregulated during latency by latency associated protein UL138 which renders cells
sensitive to drug-mediated killing.
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